Nalam Therapeutics
First-Time FounderAbout
Designing novel precision oncology therapeutics for safer, more accessible targeted therapy. Nalam develops Antibody Nanogel Conjugates (ANCs) that enable targeted delivery of combination therapies with superior drug loading capacity and payload versatility compared to traditional ADCs.
Products
ANC Platform Technology
Novel antibody-targeted drug delivery platform that enables delivery of over 85% of FDA-approved oncology small molecule drugs. Features linker-free non-covalent drug incorporation with drug-to-antibody ratios up to 20,000, superior to traditional ADCs limited to DAR of 4-8. Provides near-universal payload options with minimal optimization, stable encapsulation with 83-100% 24-hour serum retention, and readily amenable to fixed-ratio multi-drug delivery of 2+ payloads.
Click to read more
NAL-001
First-in-class dual-payload Antibody Nanogel Conjugate (ANC) for treatment of MSS/pMMR metastatic colorectal cancer. Combines two potent agents with proven complementary mechanisms that cannot be dosed systemically together due to high toxicity. Targets antigens ubiquitously expressed in tumor microenvironment while negligibly expressed in healthy cells, delivering approximately 1000x higher payload dose than traditional ADCs.
Click to read more